{"disease":{"id":"cancer-gene-mutation","name":"cancer gene mutation"},"drugs":{"marketed":[{"drug_id":"talazoparib-with-enzalutamide","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talazoparib with enzalutamide","generic_name":"talazoparib-with-enzalutamide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP enzymes and androgen receptor","drug_class":"PARP inhibitor and androgen receptor inhibitor","quality_score":10,"revenue":"2194","mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04322890","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT05721326","title":"Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition","phase":"NA","overall_status":"COMPLETED","enrollment_count":1330,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT07450612","title":"Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"San Raffaele University","has_results":false},{"nct_id":"NCT06716580","title":"EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04541381","title":"The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care","phase":"NA","overall_status":"RECRUITING","enrollment_count":860,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT04759352","title":"Telephone Versus In-person Post-test Cancer Genetic Counseling","phase":"NA","overall_status":"UNKNOWN","enrollment_count":724,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT05819905","title":"Radiomics for prEdiction of lunG cAncer biologY","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT05534854","title":"Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT03175224","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT03653546","title":"First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":492,"lead_sponsor_name":"Alpha Biopharma (Jiangsu) Co., Ltd.","has_results":false},{"nct_id":"NCT05310370","title":"HRD and Resistance to PAPPi in EOC Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT04206072","title":"D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":362,"lead_sponsor_name":"Betta Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT05110950","title":"Endobronchial Ultrasound Needle Aspiration With and Without Suction","phase":"NA","overall_status":"UNKNOWN","enrollment_count":306,"lead_sponsor_name":"Università Politecnica delle Marche","has_results":false},{"nct_id":"NCT02000622","title":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":302,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05898009","title":"Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Centre Hospitalier Universitaire de la Réunion","has_results":false},{"nct_id":"NCT06708429","title":"Lynch Syndrome X-Talk of Enteral Mucosa With Immune System","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"San Raffaele University","has_results":false},{"nct_id":"NCT07199127","title":"Duodenal Polyposis Classification in FAP","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT07222215","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":297,"lead_sponsor_name":"Kristina A. Fanucci","has_results":false},{"nct_id":"NCT04473339","title":"A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":280,"lead_sponsor_name":"CAI Hongbing","has_results":false},{"nct_id":"NCT04983628","title":"Molecular Profiling in Prostate Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false},{"nct_id":"NCT06982768","title":"How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":245,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04358562","title":"Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Second Affiliated Hospital of Nanchang University","has_results":false},{"nct_id":"NCT04592666","title":"Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":226,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06323148","title":"Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":226,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06577987","title":"Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Circle Pharma","has_results":false},{"nct_id":"NCT05598528","title":"Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)","phase":"","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"Second Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT06430502","title":"Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Wuxi People's Hospital","has_results":false},{"nct_id":"NCT06239467","title":"First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"OnKure, Inc.","has_results":false},{"nct_id":"NCT05525338","title":"Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":196,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT05933265","title":"Study of LP-184 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Lantern Pharma Inc.","has_results":false},{"nct_id":"NCT07499999","title":"Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05639751","title":"PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT06521034","title":"First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Yongchang Zhang","has_results":false},{"nct_id":"NCT06109558","title":"The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT06714617","title":"Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT03983954","title":"Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"NeoTX Therapeutics Ltd.","has_results":false},{"nct_id":"NCT04552613","title":"Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT03344965","title":"Olaparib In Metastatic Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":114,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT06163365","title":"Inherited Cancer Early Diagnosis (ICED) Study","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT05126290","title":"CTNNA1 Familial Expansion Study","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT03042221","title":"Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT04516083","title":"Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"RWJ Barnabas Health at Jersey City Medical Center","has_results":false},{"nct_id":"NCT04859543","title":"Pediatric Prospective Personalized Immune and Target Identification Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Masaryk University","has_results":false},{"nct_id":"NCT04556292","title":"A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT03846310","title":"A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT06270082","title":"Study of IK-595 in RAS- or RAF-altered Advanced Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":75,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT06238882","title":"Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.","phase":"NA","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"Instituto Nacional de Cancerologia de Mexico","has_results":false},{"nct_id":"NCT06663007","title":"RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT05724004","title":"Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT03829410","title":"Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Cardiff Oncology","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}